Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dronedarone: an amiodarone analogue.

Sheila A Doggrell1, Jules C Hancox

  • 1Doggrell Biomedical Communications, Auckland, New Zealand. s_doggrell@yahoo.com

Expert Opinion on Investigational Drugs
|April 23, 2004
PubMed
Summary

Dronedarone, an amiodarone analogue, shows promise in preventing atrial fibrillation relapses but requires further study due to safety concerns in heart failure patients. Its effectiveness against other arrhythmias is still under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same author

Quantitative analysis of trafficking defects induced by heterozygous expression of hERG voltage sensor domain variants.

Channels (Austin, Tex.)·2026
Same author

Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?

Expert opinion on pharmacotherapy·2026
Same author

Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?

Expert opinion on investigational drugs·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Transporters.

British journal of pharmacology·2025
Same author

Does varenicline promote abstinence in youths who vape?

Expert opinion on pharmacotherapy·2025

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Amiodarone is an effective antiarrhythmic drug with a low risk of pro-arrhythmia but significant extra-cardiac side effects.
  • Development of amiodarone analogues aims to mitigate side effects while retaining efficacy.
  • Dronedarone is a non-iodinated amiodarone derivative with multiple ion channel and receptor actions.

Purpose of the Study:

  • To evaluate the efficacy and safety of dronedarone as an antiarrhythmic agent.
  • To compare dronedarone's pharmacological profile with amiodarone.
  • To assess dronedarone's role in managing atrial fibrillation and other arrhythmias.

Main Methods:

  • Dronedarone's effects on cardiac ion channels (Na+, K+, Ca2+) and adrenoceptors were investigated.
  • Pharmacological actions were compared to amiodarone, including thyroid receptor effects.
  • Efficacy was assessed in animal models of ischemia-reperfusion arrhythmias and in the Dronedarone Atrial Fibrillation Study After Electrical Cardioversion (DAFNE) clinical trial.

Main Results:

  • Dronedarone inhibits Na+, K+, and Ca2+ currents, with potent effects on atrial K+ currents and L-type calcium current.
  • It acts as an antagonist at alpha- and beta-adrenoceptors and has minimal thyroid receptor activity.
  • Dronedarone demonstrated greater potency than amiodarone in animal models and showed efficacy in preventing atrial fibrillation relapses in the DAFNE trial.

Conclusions:

  • Dronedarone exhibits a distinct pharmacological profile compared to amiodarone, with potential for atrial fibrillation management.
  • The ANDROMEDA trial raised safety concerns regarding increased mortality in heart failure patients.
  • Further research is necessary to definitively establish dronedarone's advantages over amiodarone and other analogues.

Related Experiment Videos